Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.62 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.62 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | PRKCA | P17252 | 4/20 | 0.62 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.62 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.62 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.62 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.58 |
| ▸ | SELP | P16109 | 1/20 | 0.54 |
| ▸ | FABP3 | P05413 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL547251 | 1.00 | ALDH1A1 (0.63) | ALDH1A1LMNALPAR3LPAR1ENPP2 | |
| SCHEMBL3407184 | 1.00 | ALDH1A1 (0.63) | ALDH1A1LMNALPAR3LPAR1ENPP2 | |
| SCHEMBL37548 | 1.00 | ALDH1A1 (0.63) | ALDH1A1LMNALPAR3LPAR1ENPP2 | |
| SCHEMBL3409080 | 1.00 | ALDH1A1 (0.63) | ALDH1A1LMNALPAR3LPAR1ENPP2 | |
| SCHEMBL41701 | 1.00 | ALDH1A1 (0.63) | ALDH1A1LMNALPAR3LPAR1ENPP2 | |
| SCHEMBL16598280 | 1.00 | ALDH1A1 (0.63) | ALDH1A1LMNALPAR3LPAR1ENPP2 | |
| SCHEMBL42345 | 1.00 | ALDH1A1 (0.63) | ALDH1A1LMNALPAR3LPAR1ENPP2 | |
| SCHEMBL15052353 | 1.00 | ALDH1A1 (0.63) | ALDH1A1LMNALPAR3LPAR1ENPP2 | |
| Ammonia Solution, Strong SCHEMBL14632885 | 0.99 | ALDH1A1 (0.61) | ALDH1A1LMNALPAR3LPAR1ENPP2 | |
| Ammonia Solution, Strong SCHEMBL14632795 | 0.99 | ALDH1A1 (0.61) | ALDH1A1LMNALPAR3LPAR1ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090134323-A1 | MULTIDIMENSIONAL MASS SPECTROMETRY OF SERUM AND CELLULAR LIPIDS DIRECTLY FROM BIOLOGIC EXTRACTS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-05-28 | — | — | US | disclosed |
| US-7510880-B2 | Multidimensional mass spectrometry of serum and cellular lipids directly from biologic extracts | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-03-31 | — | — | US | disclosed |
| US-20070265216-A1 | ENHANCED MEDICAL TREATMENT IN DIABETIC CARDIOMYOPATHY | WASHINGTON UNIVERSITY IN ST. LOUIS | 2007-11-15 | — | — | US | disclosed |
| US-20070148779-A1 | Multidimensional mass spectrometry or serum and celluar lipids directly from biologic extracts | WASHINGTON UNIVERSITY IN ST. LOUIS (US) | 2007-06-28 | — | — | US | disclosed |
| US-20040191916-A1 | Multidimensional mass spectrometry of serum and cellular lipids directly from biologic extracts | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265216-A1 | ENHANCED MEDICAL TREATMENT IN DIABETIC CARDIOMYOPATHY | TNNI3, TNNT2, TNNC1 | ALDH1A1 3106/4885LMNA 146/4885LPAR3 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.